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ABSTRACT 
Background: Human papillomavirus serodynamics following infection has never been evaluated 
prospectively among women living with HIV (WLHIV). We determined HPV seroprevalence, 
seroconversion and cervical HPV-DNA acquisition among WLHIV.  
Methods: Prospective study of 604 WLHIV in Johannesburg, South Africa aged 25-50 years. At 
baseline and 16 months later (endline), type-specific antibodies to HPV-types 
(HPV6/11/16/18/31/33/35/39/45/52/56/58/59/68/73) were measured using HPV pseudovirions and 
corresponding cervical HPV-DNA genotypes detected using INNO-LiPA.  
Results:  Seroprevalence of any-HPV type was 93.2% and simultaneous seropositivity for HPV-types 
of the bivalent (HPV16/18), quadrivalent (HPV6/11/16/18) and nonavalent 
(HPV6/11/16/1831/33/45/52/58) vaccines were 21.4%, 10.9% and 2.8%. Among 219 women with cervical 
HPV-DNA but seronegative for the same-type and without high-grade cervical intraepithelial 
neoplasia at baseline, 51 (23.3%) had type-specific seroconversion at endline. Among these women, 
the risk of type-specific seroconversion was higher among recent antiretroviral therapy users 
(ART≤2 years vs. ART-naive: adjusted OR=2.39, 95%CI:1.02-5.62), and lower among women with low 
CD4+ at endline (≤350 vs. >350 cells/mm3: aOR=0.51, 95%CI:0.24-1.07). Risk of cervical HPV DNA 
acquisition was significantly lower in women who were seropositive for HPV18, 35 and 58 at 
baseline.  
Conclusion:  WLHIV have evidence of seroconversion in response to baseline HPV-DNA, dependent 
on CD4+ count and ART. Baseline HPV seropositivity confers limited protection against some HPV 
types.  
 
Key words: human papillomavirus (HPV); serology; antibodies; HIV; Africa  
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INTRODUCTION 1 
As women living with HIV (WLHIV) are experiencing longer life expectancy due to increased 2 
availability of antiretroviral therapy (ART), many remain at high risk of infection with HPV, acquiring 3 
anogenital warts (AGW), and progressing to cervical and other genital cancers. Primary prevention 4 
of HPV through vaccination can reduce the burden of disease and on screening and treatment 5 
services. The bivalent and quadrivalent HPV vaccines target two high-risk (HR)-HPV types (HPV16 6 
and 18) responsible for about 70% of cervical cancers[1], whereas the nonavalent vaccine protects 7 
against a wider range of HR-HPV types (HPV16/18/31/33/45/52/58), as well as types causing AGW 8 
(HPV6/11) and is estimated to prevent up to 90% of cervical cancers in women from the general 9 
population[1-3].  10 
There is limited evidence of the serological response to HPV infection among WLHIV. The evidence 11 
regarding protection against re-infection for the same HPV type induced after natural infection is 12 
also unclear. A recent meta-analysis of 14 studies among 24,000 individuals (90% women) from 13 
Europe, North America, Latin America, Asia and Australia investigating the potential protective 14 
effect of naturally acquired type-specific antibodies[4] reported 30-35% protection against 15 
subsequent infection with HPV16 (pooled relative risk [RR]=0.65, 95% confidence interval [CI]:0.50-16 
0.80) and HPV18 (RR=0.70, 95%CI:0.43-0.98) among women in the general population. However, 17 
seropositivity to a wider range of HPV types and possible seroprotection following natural 18 
infection have not been evaluated among WLHIV. An improved understanding of HPV type-specific 19 
serological responses in such high-risk populations and their risk of both new infection and 20 
reinfection is needed to guide targeted HPV control efforts, including possible use of HPV 21 
vaccination.  22 
We conducted a large prospective study of cervical cancer screening in a cohort of WLHIV in 23 
Burkina Faso and South Africa (HARP, HPV in Africa Research Partnership)[5]. In this paper, among 24 
women enrolled in the HARP study in South Africa, we evaluated HPV seroprevalence and 25 
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concordance of HPV DNA with same-type seropositivity at baseline for 15 HPV genotypes. Second, 26 
among women without high-grade cervical intraepithelial neoplasia (CIN2+) at baseline, we 27 
evaluated the factors associated with HPV seroconversion following baseline HPV-DNA infection, 28 
and risk of incident HPV-DNA detection among women seropositive for same-type HPV at baseline.  29 
 30 
METHODOLOGY 31 
Study population and specimen collection 32 
The HARP cohort study has been described in detail elsewhere[5]. In South Africa, women were 33 
recruited from HIV treatment centres and surrounding communities in Johannesburg from 34 
December 2011 to October 2012. Inclusion criteria were being HIV-1 seropositive, aged 25-50 years 35 
and resident in the city. Exclusion criteria were history of prior treatment for cervical cancer, 36 
previous hysterectomy, and being pregnant or less than 8 weeks postpartum. Eligible participants 37 
provided signed informed consent. Enrolment was stratified in a 2:1 ratio of ART-users:ART-naïve. 38 
Participants were followed-up every 6 months for CD4+ T-lymphocytes count and up to scheduled 39 
month 18 visit (endline) when procedures similar to baseline were repeated. Ethical approval was 40 
granted by the University of Witwatersrand, Johannesburg, and the London School of Hygiene and 41 
Tropical Medicine.    42 
Laboratory testing 43 
HPV-DNA genotyping was performed at baseline and endline using the INNO-LiPA HPV genotyping 44 
Extra® assay (Fujirebio, Courtaboeuf, France). Analysis of HPV DNA positivity was restricted to the 45 
15 types covered by the serology assay (HPV6/11/16/18/31/33/35/39/45/52/56/58/59/68/73) with HR-46 
HPV being similarly defined with the following 12 types: HPV16/18/31/33/35/39/45/52/56/58/59/68[6].  47 
HPV antibodies were detected using a multiplexed binding assay, which uses pseudovirions (PsV) 48 
as antigens and detects HPV type specific IgG antibodies (PsV-Luminex). Serology was performed 49 
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for ‘carcinogenic/probable carcinogenic’ types HPV16/18/31/33/35/39/45/52/56/58/59/68 (except the 50 
HR-HPV type 51) and the low-risk (LR) types HPV6/11/73 at Karolinska Institute, Stockholm, 51 
Sweden[7, 8]. Serum samples were analysed in a 1:50 and 1:150 dilutions. Cut-off values to define 52 
seropositivity were calculated independently for each HPV type by analysing the mean 53 
fluorescence intensity unit (MFI) values obtained from a panel of 100 Swedish children’s sera (≤12 54 
years old). The cut-off algorithm was as recommended by the global HPV LabNet (mean MFI value 55 
of a negative control serum panel plus 3 standard deviations)[9]. If this cut-off value was 56 
unreasonably low (less than 400 MFI), 400 MFI was used as cut-off to have a sensitivity and 57 
specificity similar to classical HPV ELISAs[10].  58 
Statistical analysis 59 
Cervical HPV DNA status 60 
Women were considered “HPV-DNA positive” if positive by INNO-LiPA for any of the HPV types 61 
included in the serology assay, and “HPV-DNA negative” if negative for all of these types. HPV-DNA 62 
genotype-specific persistence was defined as being positive for the same type at baseline and 63 
endline visits. Type-specific clearance was defined as being positive for a specific type at enrolment 64 
and negative for that type at endline visit. Given that no woman was simultaneously infected by all 65 
15 HPV types, all women were at risk of acquiring at least one HPV infection and all were included 66 
in the analysis of associations of baseline seropositivity with same-type HPV DNA incidence.  67 
HPV serology status 68 
HPV serology results are presented as binary results (positive and negative for a given type) based 69 
on the pre-assigned cut-off. Overall and type-specific or group (vaccine targets) HPV 70 
seroprevalence was defined as being seropositive for any/type-specific/grouped types 71 
respectively, among women with serology data at baseline. HPV type-specific seroconversion was 72 
defined as being HPV-DNA positive (i.e., recently exposed) and same-type seronegative at baseline 73 
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that became same type seropositive at endline, irrespective of the DNA status at endline. We also 74 
analysed type-specific seropersistence (having same-type detectable antibody at baseline and 75 
endline) and seroreversion (seropositive for a specific HPV type at baseline and seronegative for 76 
the same type at endline) among all women who were seropositive for any HPV type at baseline, 77 
irrespective of their cervical HPV-DNA status.  78 
Longitudinal analyses were restricted to women without prevalent CIN2+ at baseline, as the 79 
natural history of HPV infection and serology dynamics in women with CIN2+ would be difficult to 80 
interpret since many women had received ablative therapy. 81 
For comparison of HPV seropositivity among type-specific HPV DNA positive and DNA negative 82 
WLHIV at baseline, prevalence ratios (PRs) were obtained from logistic regression using marginal 83 
standardization to estimate PRs, and the delta method to estimate 95% confidence intervals 84 
(CI)[11]. Associations between HPV seroconversion and exposure variables were estimated with 85 
generalised estimating equations (GEE) to account for seropositivity by multiple HPV types within 86 
women[12]. To explore associations of HPV seroconversion with HIV-related factors, pre-specified 87 
analyses included stratification by ART duration (≤2 or >2 years) and CD4+ cell counts (≤350 or >350 88 
cells/mm3) at baseline and endline, and HIV-1 viral suppression (plasma HIV-1 RNA <1000 or ≥1000 89 
copies/ml) at baseline. Stable high CD4+ count was defined as having CD4+ counts >500 cells/mm3 90 
at baseline, month 12 (intermediate) and endline visits. Multivariable analyses were adjusted for 91 
socio-demographic and behavioral factors which were independently associated with HPV 92 
seroconversion. For associations of baseline seropositivity with HPV-DNA incidence, logistic 93 
regression was used to estimate odds ratios (OR) and 95%CI. Data were analysed using Stata 94 
version 14 (Stata Statistical Software, College Station. TX: Stata Corporation).  95 
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RESULTS  96 
Study population  97 
A full description of HARP study participants has been published elsewhere[5]. Of the 623 WLHIV 98 
enrolled in South Africa, the median age at enrolment was 34 years (interquartile range [IQR]: 30-99 
40), and median time in follow-up was 16 months (IQR: 15.6-16.8). In total, 604 (97.0%) WLHIV had 100 
valid results for both HPV serology and genotyping at baseline (Figure 1). Of these, 390 (64.6%) 101 
reported taking ART throughout the study period with a median duration of 3.4 years (IQR:1.8-5.3) 102 
during foll0w-up, 42 (7.0%) initiated ART during follow-up and 172 (28.5%) remained ART-naive 103 
throughout the study. The median baseline CD4+ cell counts of ART users, ART initiators and ART-104 
naive were 421 cells/mm3 (IQR:285-580), 333 cells/mm3 (IQR:260-403) and 475 cells/mm3 (IQR:366-105 
625), respectively. CD4+ cell counts change per year were +7 cells/mm3 (IQR: -55 to 89), +83 106 
cells/mm3 (IQR: -33 to 205) and -36 cells/mm3 (IQR: -119 to 24) in the three groups, respectively.   107 
 108 
HPV seroprevalence at baseline 109 
Seroprevalence of any of 15 HPV types was 93.2% (95%CI:90.9-95.1%), of whom 89.9% (506/563) 110 
were seropositive for multiple types (Figure 2). The seroprevalence of any 12 HR-HPV type was 111 
90.7% (95%CI:88.1-92.9%). Overall, almost all women (n=591; 97.8%) were positive by either serology 112 
or DNA for any HPV, and 583 (96.5%) for any HR-HPV types.  113 
Seroprevalence was highest for HPV31 (59.6%), followed by HPV58 (54.8%) and HPV16 (43.1%) 114 
(Figure 2). The seroprevalence of any HPV genotypes included in the bivalent (HPV16/18), 115 
quadrivalent (HPV6/11/16/18) or nonavalent (HPV6/11/16/18/31/33/45/52/58) vaccines were 59.3%, 116 
73.5% and 87.6%, respectively. Simultaneous seropositivity for all HPV types included in the bivalent, 117 
quadrivalent and nonavalent vaccines was 21.4%, 10.9% and 2.8%, respectively.   118 
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Correlation of HPV-DNA and antibody-specific prevalence  119 
Of 472 women DNA positive for any of the 15 HPV types at baseline, 279 (59.1%) were seropositive 120 
for the same HPV type (range by type: 25.5% for HPV45 to 68.9% for HPV31; Table 1). The type-121 
specific HPV seroprevalence was significantly higher among those with same-type DNA positive 122 
compared to same-type DNA negative for HPV31, HPV35, HPV39, HPV52, HPV58 and low-risk type 123 
HPV11. 124 
HPV seroconversion and association with DNA persistence and clearance 125 
 Of all 451 women without CIN2+ at enrolment who were followed-up until endline, genotyping and 126 
serology data at baseline and endline were available for 433 (96.0%; Figure 1). There were 219 127 
women who were HPV-DNA positive and same-type seronegative at baseline. Same-type 128 
seroconversion was observed for 23.3% (51/219), irrespective of DNA status during follow-up.  129 
When considering the total number of baseline infections as denominator (n=326), there were 56 130 
(17.2%) HPV seroconversion events (Table 2). Risk of type-specific seroconversion was highest for 131 
HPV31 (53.9%) and HPV33 (33.3%) and lowest for HPV18 (17.1%) and HPV16 (2.4%). Overall, risk of 132 
type-specific seroconversion was greater with same-type persistent DNA infection compared to 133 
cleared infection; irrespective of newly detected DNA during follow-up (Table 2: any HPV type 134 
seroconversion: 23.0% vs. 15.1%; crude OR=1.75, 95%CI:0.95-3.24; aOR=1.56, 95%CI:0.78-3.13, adjusted 135 
for injectable contraception and CD4+ cell count at endline).  136 
 137 
HIV-related factors associated with HPV seroconversion  138 
When considering the number of baseline infections as denominator, the risk of HPV 139 
seroconversion was similar by baseline CD4+ count (Table 3) but lower with low endline CD4+ 140 
(≤350 vs. >350 cells/mm3:10.8% vs. 19.4%; aOR=0.51, 95%CI:0.24-1.07, adjusted for injectable 141 
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contraceptive use), and this association was significant among ART users only (≤350 vs. >350  142 
cells/mm3: 8.0% vs. 26.3%; aOR=0.25, 95%CI: 0.08-0.75).   143 
The highest risk of seroconversion was among short-duration ART users (≤2 years ART vs. ART-144 
naïve at endline: 24.6% vs. 14.2%; aOR=2.39, 95%CI:1.02-5.62, adjusted for injectable contraceptive 145 
use and endline CD4+ cell count). HPV seroconversion was also more likely among women who 146 
reported high adherence to ART at baseline (60-90% vs. <60% adherence: 22.4% vs. 7.1%; aOR=8.93, 147 
95%CI:1.13-70.36).  148 
 149 
Newly detected HPV DNA over 16 months according to type-specific seropositivity at baseline  150 
Among the 433 women with genotyping and serology data at both visits (Figure 1), 221 (51.0%) 151 
women had newly detected HPV-DNA at endline, with a total of 327 incident infections (Table 4). 152 
The risk of incident infection was lower among women who were same-type seropositive 153 
compared to seronegative at baseline for HPV18 (1.5% vs. 6.4%; aOR=0.14, 95%CI:0.02-0.80, adjusted 154 
for baseline CD4+ cell count, ART status and seropositivity for any type from same HPV 155 
phylogenetic family); HPV35 (4.1% vs 11.9%; aOR=0.26, 95%CI:0.10-0.68) and HPV58 (1.8% vs. 5.4%; 156 
aOR=0.19, 95%CI:0.04-0.89). Conversely, the risk was higher among those with same-type baseline 157 
seropositivity for HPV45 (10.5% vs. 4.0%) but the association did not persist following adjustment 158 
for seropositivity from same HPV phylogenetic family (aOR=2.81, 95%CI:0.87-9.04), although 159 
numbers were small.    160 
Among 403 women with detectable antibodies at baseline, 384 (95.3%) had the same type 161 
detected again at endline. HPV-DNA incidence was similar among women with seropersistence and 162 
seroreversion (Table 4).  163 
 164 
10 
 
 
DISCUSSION 165 
This prospective study of serological dynamics for 15 HPV types among WLHIV found a very high 166 
seroprevalence at baseline, new-type seroconversion and type-specific seropersistence 16 months 167 
later. In keeping with these findings, these women also had high prevalence, incidence and 168 
persistence of HR-HPV-DNA, including multiple type infection[5]. To our knowledge, this is the first 169 
study to report HPV seroconversion in conjunction with HPV-DNA over time among WLHIV.  170 
We report a similar seroprevalence for types HPV6, 11 and 16 as reported elsewhere among WLHIV 171 
in South Africa[13] and the USA[14]. We found that the proportion of women who were 172 
seropositive for multiple HPV types was higher than the prevalence of multiple HPV-DNA infections 173 
at baseline, suggesting prior exposure to these types. Although the prevalence of antibodies to 174 
HPV vaccine types was high, the simultaneous seropositivity for all 9vHPV vaccine types was 175 
observed in a minority of women.   176 
After 16 months of follow-up, we report evidence of  same-type seroconversion, which was higher 177 
among women with same-type persistence compared to cleared infection at endline. 178 
Seroconversion rates reported in this study are lower than those reported among HIV-negative 179 
women. A study among 588 HIV-negative HPV-unvaccinated women aged 18-20 years[15] reported 180 
seroconversion rates of 59.5%, 54.1% and 68.8% for HPV16, HPV18 and HPV6, respectively within 18 181 
months of detection of same-type incident infection, and was more likely among women with 182 
same-type persistent infection, as found in our study. Similarly, among 6,528 women in Costa 183 
Rica[16] 21.7% of women with HPV-DNA at baseline had seroconversion for HPV16 over a median 184 
6.4 years, and was higher among women with persistent compared to cleared infection. While 185 
there are no studies among WLHIV to make any comparison, seroconversion among 245 HIV-186 
infected men who have sex with men (MSM) in the Netherlands following anal or penile HPV 187 
infection was 23% over 12 months[17] and 42% over 24 months among 281 HIV-infected MSM 188 
initiating ART in Switzerland[18].  189 
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Seroconversion in our study varied by HPV type, and was highest for HPV31 and lowest for HPV16. 190 
The type-specific seroconversion rates reflected the type-specific infection states at follow-up. The 191 
overall incident and persistent HPV-DNA was higher for HPV16 than for other types[19]. The lower 192 
seroconversion and subsequent increased risk of HPV16 incidence and persistence could be a result 193 
of its immune evasion mechanisms[20].  194 
Seroconversion was more frequent among women with higher CD4+ cell count (>350 cells/mm3) 195 
at endline and this association was observed in the short-duration (≤2 years) ART users only. A 196 
study among 281 MSM initiating ART and followed for a median of 2 years[18] reported that those 197 
with lower nadir CD4+ cell count (<200 cells/mm3) at ART initiation had the highest seroconversion 198 
rates, compared to MSM initiating ART at higher CD4+ cell count (≥350 cells/mm3). It is possible 199 
that ART-related immune reconstitution during follow-up may have promoted seroconversion, and 200 
this was highest among men with the lowest CD4+ cell count, possibly because they had the 201 
greatest CD4+ cell count recovery. Although nadir CD4+ cell count was not available in our study, 202 
short-duration ART users at endline had a lower baseline CD4+ cell count compared to both the 203 
long-duration ART or ART-naïve women (median CD4+ count of 324, 461 and 497 cells/mm3, 204 
respectively[5]). Although baseline CD4+ cell count was not associated with seroconversion, the 205 
subsequent increase in CD4+ cell count at endline through ART-initiated immune reconstitution 206 
(median CD4+ cell count among short duration ART users increased by +103 cells/mm3 [IQR: -13 to 207 
196]) may have stimulated seroconversion among the recent ART users in response to the high 208 
rate of HPV-DNA persistence reported in this cohort[5]. This is also supported by our findings of 209 
higher seroconversion rates among women with better ART adherence.  210 
An additional explanation for higher seroconversion among short-duration ART users is linked to 211 
the higher HPV-DNA prevalence, persistence and lack of viral clearance in this group compared to 212 
prolonged ART users in this cohort[5]. It can be speculated that among recent ART initiatiors, 213 
immune reconstitution may have been not entirely effective to prevent persistence in the short-214 
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term[5]. Our finding of an association of seroconversion with higher endline (but not baseline) 215 
CD4+ count in this study, may reflect the delay required for seroconversion to occur after infection, 216 
which might also be influenced by the initial state of immunosuppression. As seen in young HIV-217 
negative women, HPV16 seroconversion occurred between 6 to 12 months after DNA 218 
detection[15]. In our study, the duration of HPV-DNA infection at baseline could not be determined.  219 
Women taking ART for a prolonged duration (>2 years) had similar low seroconversion rate as ART-220 
naïve women. This may be because women on prolonged ART and strong immune recovery may 221 
have fewer prevalent and persistent infections[5], which would be required to trigger 222 
seroconversion. The more puzzling finding, however, is that ART-naïve women in this study had as 223 
high rates of persistent HR-HPV infection as short-duration ART users, and their CD4+ cell count at 224 
either timepoint was not associated with seroconversion. Increases in HPV seropositivity by ART 225 
status have been shown to be independent of CD4+ count in other studies among MSM[18] and 226 
WLHIV[14]. No study has yet compared seroconversion among ART users and ART-naïve women 227 
following natural infection, but vaccination studies among WLHIV have shown that, while 228 
seroconversion rates are similar among ART users and ART-naive women in the US and Puerto 229 
Rico[21], HPV16 and HPV18 antibody titres were lower among ART-naïve but comparable between 230 
HIV-negative and ART users[21]. These data suggest there may be some beneficial impact of ART 231 
in promoting seroconversion.  232 
We found evidence that HPV antibodies detected at baseline provided protection against DNA 233 
detection only for HPV18, 35 and 58, for which infection rates were lower.  A recent meta-analysis, 234 
which assessed whether naturally acquired immunity conferred protection against subsequent 235 
infection by the same type[4], reported that HIV-negative women with antibodies against HPV16 236 
and HPV18 had a modest 35% and 30% lower risk of subsequent infection, respectively against the 237 
corresponding type. We found no protection conferred by HPV16 antibodies against HPV16 DNA 238 
detection in this study. Others have reported that HPV16 is better able to evade the host immune 239 
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surveillance relative to other HPV types[22], which may explain its predominance in high-grade 240 
cervical lesions in HIV-positive and HIV-negative women[3]. A prospective study among 829 WLHIV 241 
risk-matched with 413 HIV-negative women in the US[23] reported no statistically significant 242 
difference in the risk of reinfection of any HR-HPV (HPV16/18/31/35/45) among women with same-243 
type seropositivity compared to same-type seronegative at baseline over a median 4.5 years, with 244 
the exception of a reduced risk with HPV45.   245 
Other studies have evaluated whether HPV antibodies detected at two or more time points were 246 
associated with subsequent detection of same-type HPV-DNA among HIV-negative women. A 247 
prospective study with longitudinal serology measurements among 608 HIV-negative women  248 
seen at 6-month intervals for 3 years in the US[24] reported a reduction in risk of subsequent HPV16 249 
detection among women with a sustained high level of HPV16 antibody (seropositivity at two or 250 
more time points) and its phylogenetically related types (HPV31/33/58). HPV seropersistence in our 251 
study over 16 months was very high, however there was limited evidence that WLHIV who had 252 
type-specific seropersistence had lower HPV-DNA detection compared to women with 253 
seroreversion at endline. This finding suggests that seroprevalence, seropersistence and 254 
seroreversion are not good markers of protection against subsequent DNA detection. Given the 255 
limited evidence that natural immunity can protect against subsequent infection[4], a multivalent 256 
vaccine such as the nonavalent vaccine would be beneficial given that 55% of WLHIV in this study 257 
had multiple HR-HPV infection at baseline, 18% had multiple persistent types at endline[19] and few 258 
women were simultaneously infected by all vaccine-types.  259 
This study was constrained by a limited number of visits between baseline and endline and the 260 
overall relatively short follow-up duration. Therefore, we cannot establish whether the 261 
seroconversion event occurred in response to either an infection which persisted during follow-up 262 
or a baseline infection which cleared followed by new DNA detection of the same type. Moreover, 263 
when evaluating the risk of new DNA detection according to same-type seropositivity at baseline, 264 
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we cannot exclude the possibility that the infection detected at 16-months was a reinfection or a 265 
recurrence of a latent undetected infection. However, infrequent condom use, presence of other 266 
sexually transmitted infection or reproductive tract infections (including Chlamydia trachomatis, 267 
Trichomonas vaginalis, and bacterial vaginosis), vaginal cleansing and low CD4+ counts at 268 
enrolment  were associated with new DNA detection (data not shown). These factors may point 269 
to behaviours or factors enhancing the risk of a new sexually acquired infection, or modifiers of 270 
vaginal biome or mucosal immunity which may enhance the possibility of reactivation of a latent 271 
HPV infection.  Analysis of new DNA detection over 16 months according to type-specific positivity 272 
was constrained by the small numbers of individual genotype positivity. This study had several 273 
important strengths, including its longitudinal design, the availability of serology and genotyping 274 
data at both time points. It is the first study to measure HPV serodynamics longitudinally among 275 
WLHIV.  276 
In conclusion, this study shows that WLHIV have high HPV seroprevalence and sero-persistence of 277 
type-specific antibodies. We found evidence of seroconversion over 16 months that was 278 
dependent on CD4+ cell count at endline. The high HPV incidence and the limited evidence that 279 
naturally acquired antibodies protect against new DNA detection combined with the fact that even 280 
though WLHIV have multiple infections, few have been infected with all preventable infections, 281 
suggest that WLHIV could benefit from highly multivalent HPV vaccination. Studies, including 282 
mathematical modelling studies, assessing the efficacy and cost-effectiveness of nonavalent HPV 283 
vaccine are warranted in this population.  284 
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Figure 1 Study flowchart  285 
 286 
Legend:  287 
¶given that no woman was infected by all 15 HPV ypes, all women were at risk of acquiring at least one-HPV;  *DNA positive for any 15 288 
type (HPV6/11/16/18/31/33/35/39/45/52/56/58/59/68/73); §DNA negative for all 15 type 289 
(HPV6/11/16/18/31/33/35/39/45/52/56/58/59/68/73) 290 
Enrolled; N=623
Genotyping and serology;n=604 (97.0%) 
Eligible for follow-up: n=480 
Returned for Endline Visit; n=451 (94.9%) 
Genotyping and serology, n=433 (96.0%)¶
HPV-DNA positive* at 
baseline; 
n=324 (74.8%)
Same-type seropositive at 
baseline; 
n=105 (32.4%)
Same-type seronegative at 
baseline; 
n=219 (67.6%)
Same-type seroconversion, 
n=51 (23.3%) 
No seroconversion, 
n=168 (76.7%)
HPV-DNA negative§ at 
baseline; 
n=109 (25.2%)
Loss to Follow-Up, n=29 
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Figure 2. HPV type seroprevalence and DNA prevalence among 604 women living with HIV in 291 
Johannesburg, South Africa 292 
Panel A 293 
 294 
 295 
Panel B 296 
 297 
 298 
Legend:  299 
Panel A: Prevalence of combination of HPV types: * Any HPV type prevalence defined as positive for at least one HPV type 300 
(6/11/16/18/31/33/35/39/45/52/56/58/59/68/73) at baseline; Any HR-HPV type prevalence defined as positive for at least one HR type 301 
(16/18/31/33/35/39/45/52/56/58/59/68) at baseline; Any 9V=Positive for any of HPV6/11/16/18/31/33/45/52/58; Any 9V-HR=Positive for any of 302 
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HPV16/18/31/33/45/52/58;  Any 4V= Positive for any of HPV6/11/16/18; Any 4V-LR= Positive for any of HPV6/11; Any 2V= Positive for any of 303 
HPV16/18; All 9V=Positive for ALL of HPV6,11,16,18,31,33,45,52 and 58; All 9V-HR=Positive for ALL of HPV16,18,31,33,45,52 and 58; All 304 
4V=Positive for ALL of HPV6,11,16 and 18; All 2V=Positive for BOTH HPV16 and 18; All 4V-LR=Positive for BOTH HPV6 and 11. Panel B: 305 
Prevalence of individual HPV types.  306 
 307 
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Table 1. Comparison of HPV seropositivity among type-specific HPV DNA positive and DNA negative women living with HIV (N=604) at baseline 308 
 DNA positive Seropositive 
Seropositive/ 
DNA positive  
DNA negative Seropositive 
Seropositive/ 
DNA negative  
aPR (95%CI)1 
(N) (n) (%) (N) (n) (%)  
Bi-/Quadrivalent types        
HPV6 33 14 42.4 571 241 42.2 0.94  (0.60-1.49) 
HPV11 33 19 57.6 571 197 34.5 1.71  (1.24-2.35) 
HPV16 115 50 43.5 489 210 42.9 1.02  (0.80-1.31) 
HPV18 89 34 38.2 515 193 37.5 1.10  (0.83-1.47) 
       
 
Additional Nonavalent types 
      
 
HPV31 61 42 68.9 543 318 58.6 1.28  (1.08-1.52) 
HPV33 48 25 52.1 556 219 39.4 1.25  (0.91-1.71) 
HPV45 47 12 25.5 557 107 19.2 1.42  (0.84-2.42) 
HPV52 146 60 41.1 458 129 28.2 1.54  (1.19-1.98)   
HPV58 54 36 66.7 550 295 53.6 1.27  (1.03-1.55)    
       
 
Non-vaccine types       
 
HPV35 99 59 59.6 505 197 39.0 1.52  (1.23-1.88)   
HPV39 48 25 52.1 556 199 35.8 1.46  (1.08-1.98) 
HPV56 58 20 34.5 546 183 33.5 1.01  (0.68-1.49)   
HPV59 11 6 54.5 593 201 33.9 1.59  (0.90-2.79)   
HPV68 33 12 36.4 571 166 29.1 1.33  (0.82-2.14)     
HPV73 10 4 40.0 594 130 21.9 1.15  (0.35-3.74) 
        
Any HPV a,b 472 279 59.1 a 132 119 90.2 b  
Any HR-HPV a,b 456 267 58.6 a 148 127 85.8 b  
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aHPV type seropositive among DNA positive for the same type; b Any type HPV seropositive among DNA negative for all types; 1adjusted Prevalence Ratio [PR] for type-specific seroprevalence if same-type DNA 309 
positive compared to DNA negative, adjusted for injectable contraception, HIV viral suppression (plasma HIV-1 RNA <1000 copies/ml) found to be associated with any HPV seroprevalence at baseline, and CIN2+ 310 
status.  311 
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Table 2. Type-specific seroconversion at 16 months among 219 women living with HIV without CIN2+ at baseline  312 
 
All participantsa Participants with HPV DNA persistenceb Participants with HPV DNA clearancec 
 
DNA+ & sero-  
at baseline 
Seroconversion events 
DNA+ & sero- at 
baseline 
Seroconversion events 
DNA+ & sero- at 
baseline 
Seroconversion events 
 
N infections n (%)a N infections n (%)b N infections n (%)c 
 
      
HPV16 41 1 (2.4) 11 1 (9.1) 30 0 (0.0) 
HPV18 41 7 (17.1) 14 3 (21.4) 27 4 (14.8) 
HPV6 13 3 (23.1) 0 0 (0.0) 13 3 (23.1) 
HPV11 13 2 (15.4) 3 1 (33.3) 10 1 (10.0) 
 
 
 
    
HPV31 13 7 (53.9) 2 2 (100.0) 11 5 (45.5) 
HPV33 15 5 (33.3) 1 1 (100.0) 14 4 (28.6) 
HPV45 25 4 (16.0) 8 1 (12.5) 17 3 (17.6) 
HPV52 63 12 (19.1) 21 6 (28.6) 42 6 (14.3) 
HPV58 12 3 (25.0) 4 1 (25.0) 8 2 (25.0) 
 
 
 
    
HPV35 26 6 (23.1) 11 3 (27.3) 15 3 (20.0) 
HPV39 19 0 (0.0) 2 0 (0.0) 17 0 (0.0) 
HPV56 26 4 (15.4) 4 1 (25.0) 22 3 (13.6) 
HPV59 4 1 (25.0) 1 0 (0.0) 3 1 (33.3) 
HPV68 13 1 (7.7) 3 0 (0.0) 10 1 (10.0) 
 
 
 
    
HPV73 2 0 (0.0) 2 0 (0.0) 0 0 (0.0) 
       
Any HPV 326 56 (17.2) 87 20 (23.0) 239 36 (15.1) 
Any HR-HPV 298 51 (17.1) 82 19 (23.2) 216 32 (14.8) 
aSeroconversion calculated among 219 women with DNA+/sero- status at baseline representing 326 infections; bSeroconversion calculated among DNA+/sero- at baseline and with type-specific persistence at 313 
endline; cSeroconversion calculated among DNA+/sero- at baseline and type-specific clearance at endline314 
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Table 3. HIV-related factors associated with HPV seroconversion at 16 months using 319 events 315 
of DNA positive/same type seronegative at baseline (among 219 women living with HIV)   316 
 N n (%) aOR (95% CI) a 
All women    
Baseline CD4+ count (cells/mm3)b 
  
 
        ≤350 96 19 (19.8) 1.19 (0.64-2.21) 
        >350 221 37 (16.7) 1.00 
Endline CD4+ count (cells/mm3)b 
  
 
        ≤350 93 10 (10.8) 0.51 (0.24-1.07) 
        >350 191 37 (19.4) 1.00 
ART status at endline    
        ART >2 years 124 22 (17.7) 1.77 (0.85-3.69) 
        ART ≤2 years 61 15 (24.6) 2.39 (1.02-5.62) 
        ART-naïve 134 19 (14.2) 1.00 
    
Baseline ART users 
  
 
HIV-1 viral suppression at baseline    
         <1000 copies/ml 146 27 (18.5) 1.00 
         ≥1000 copies/ml 26 7 (26.9) 1.91 (0.67-5.38) 
ART adherence at baselinec 
  
 
         Low adherence (<60%) 28 2 (7.1) 1.00 
         Moderate adherence (60-90%) 143 32 (22.4) 8.93 (1.13-70.36) 
Baseline CD4+ count (cells/mm3) d 
  
 
         ≤350 64 15 (23.4) 1.38 (0.64-2.96) 
         >350 106 19 (17.9) 1.00 
Endline CD4+ count (cells/mm3) e 
  
 
         ≤350 50 4 (8.0) 0.25 (0.08-0.75) 
         >350 99 26 (26.3) 1.00 
Stable high CD4+ countf    
         Yes 27 4 (14.8) 1.00 
         No 144 30 (20.8) 1.52 (0.49-4.74) 
 
ART-naïve women  
  
 
Baseline CD4+ count (cells/mm3) g 
  
 
          ≤350 32 4 (12.5) 0.71 (0.22-2.31) 
          >350 115 18 (15.7) 1.00 
Endline CD4+ count (cells/mm3) h 
  
 
          ≤350 40 6 (15.0) 1.40 (0.46-4.30) 
          >350 81 9 (11.1) 1.00 
Stable high CD4+ count f    
          Yes 27 1 (3.7) 1.00 
          No 121 21 (17.4) 5.18 (0.66-40.85) 
Adjusted Odds Ratio (aOR) using generalised estimating equation ; aAssociations with HPV seroconversion were adjusted for injectable 317 
contraception use and CD4+ count at endline which were found to be associated with any HPV type seropositivity in multivariate analysis  318 
(with exception of associations with ART at baseline when baseline CD4+ was used for adjustment); bCD4+ count at baseline available 319 
for 317; CD4+ count at endline available for 284;  cART adherence measure available  for 171 ART users at baseline;   d Baseline CD4+ count 320 
among ART users at baseline; e Endline CD4+ count among ART users throughout follow-up;  f Stable high CD4+ count was defined as 321 
having CD4+ counts >500 cells/mm3 at baseline, month 12 (intermediate) and endline visits; gBaseline CD4+ among participants who 322 
were ART-naïve at baseline; h Endline CD4+ count among participants who were ART-naïve throughout follow-up. 323 
 324 
22 
 
 
Table 4. Newly detected HPV DNA among 433 women living with HIV without CIN2+, measured over 16 months follow-up, stratified by same type 325 
seropositivity at baseline 326 
     Among seropositive at baseline 
  All participants 
Seronegative at 
baseline 
Seropositive  
at baseline 
aOR (95%CI)3 
Seropersistence  
at endline 
Seroreversion 
 at endline 
aOR (95%CI)4 
  N1 n (%)2 N1 n (%)2 N1 n (%)2  N1 n (%)2 N1 n (%)2   
Any Alpha-9 HR-HPV types                  
HPV16 366 48 (13.1) 203 25 (12.3) 163 23 (14.1) 1.48 (0.69-3.15) 135 20 (14.8) 28 3 (10.7) 1.50 (0.39-5.72) 
HPV31 394 20 (5.1) 169 8 (4.7) 225 12 (5.3) 1.12 (0.36-3.45) 204 10 (4.9) 21 2 (9.5) 0.57 (0.11-2.92) 
HPV33 408 17 (4.2) 248 11 (4.4) 160 6 (3.8) 0.70 (0.21-2.33) 143 5 (3.5) 17 1 (5.9) 0.59 (0.06-5.60) 
HPV35 374 33 (8.8) 227 27 (11.9) 147 6 (4.1) 0.26 (0.10-0.68) 110 4 (3.6) 37 2 (5.4) 0.67 (0.11-4.13) 
HPV52 327 55 (16.8) 233 41 (17.6) 94 14 (14.9) 0.77 (0.36-1.65) 82 12 (14.6) 12 2 (16.7) 0.78 (0.14-4.37) 
HPV58 404 14 (3.5) 187 10 (5.4) 217 4 (1.8) 0.19 (0.04-0.89) 191 3 (1.5) 26 1 (3.9) 0.29 (0.02-3.48) 
            
 
Any Alpha-7 HR-HPV types            
HPV18 367 17 (4.6) 235 15 (6.4)  132 2 (1.5) 0.14 (0.02-0.80) 84 2 (2.4) 48 0 (0.0)  
HPV39 397 24 (6.1) 251 14 (5.6) 146 10 (6.9) 1.69 (0.65-4.42) 83 5 (6.0) 63 5 (7.9) 0.78 (0.21-2.85) 
HPV45 403 21 (5.2) 327 13 (4.0) 76 8 (10.5) 2.81 (0.87-9.04)  37 4 (10.8) 39 4 (10.3) 1.42 (0.27-7.66) 
HPV59 424 5 (1.2) 280 4 (1.4) 144 1 (0.7) 0.41 (0.02-8.74) 107 1 (0.9) 37 0 (0.0)  
HPV68 412 26 (6.3) 299 13 (4.4) 113 13 (11.5) 4.07 (1.52-10.90) 89 11 (12.4) 24 2 (8.3) 1.30 (0.26-6.60) 
            
 
Other HPV types            
HPV56  396 16 (4.0) 264 10 (3.8) 132 6 (4.6) 1.56 (0.51-4.76) 98 5 (5.1) 34 1 (2.9) 1.51 (0.17-13.76) 
             
LR-HPV types             
HPV6 410 13 (3.2) 241 7 (2.9) 169 6 (3.6) 1.28 (0.41-4.03) 142 5 (3.5) 27 1 (3.7) 1.09 (0.12-10.26) 
HPV11 408 15 (3.7) 269 10 (3.7) 139 5 (3.6) 1.16 (0.37-3.67) 119 4 (3.4) 20 1 (5.0) 0.73 (0.08-7.07) 
HPV73 428 3 (0.7) 331 1 (0.3) 97 2 (2.1) 
28.03 (0.98-
798.1) 
72 1 (1.4) 25 1 (4.0) 
0.40 (0.02-6.73) 
 
            
Any HPV 433a 327 427b 209 (48.9) 400c 118 (29.5)       
1Number of women negative for that type at baseline; 2number of incident infections among women negative or that type at baseline; 3adjusted Odds Ratio (OR) for DNA incidence among same-type seropositive 327 
vs. seronegative at baseline, adjusted for age, smoking, condom, vaginal washing,  bacterial vaginosis, Clamydia trachomatis, Trichomonas vaginalis, CD4 count and ART status at baseline as reported in [5] and 328 
for seropositivity for HPV type from same family group, i.e. HPV16 DNA incidence adjusted seropositivity for types HPV31/33/35/52/58 (except for HPV56,6,11 and 73 due to small numbers); 4adjusted OR for DNA 329 
incidence among seropersistent vs. seroreverted at endline, adjusted for CD4+ at baseline only due to small numbers;  aAll women at risk of acquiring a HPV infection (no woman infected by all types at baseline); 330 
ball women with any HPV type seronegative and same type DNA negative at baseline; cAll women with any HPV type seropositive and same type DNA negative at baseline.   331 
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